AstraZeneca Stock Creeps Higher on Covid-19 Vaccine Update

Options traders have been much more bullish than usual of late

Deputy Editor
Sep 30, 2021 at 10:47 AM
facebook twitter linkedin


AstraZeneca PLC (NASDAQ:AZN) is in the spotlight today, after a large U.S. trial showed the drugmaker's Covid-19 vaccine demonstrated 74% efficacy in prevent symptomatic disease. That figure increased to 83.5% in individuals aged 65 and older. In response, AstraZeneca plans to file for U.S. Food and Drug Administration (FDA) approval later this year.

AstraZeneca stock was last seen up 1.1% to trade at $60.32. The equity has been volatile as of late, rallying to a Sept. 24, annual high of $61.29, which was preceded by a steep dip that the ascending 150-day moving average was able to capture. Year-to-date, the equity is up 20.5%.  

The options pits are flashing a penchant for bullish bets. This is per AstraZeneca stock's 10-day call/put volume ratio of 10.21 at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX). This ratio sits higher than 94% of readings from the past year, showing puts being picked up at a much faster-than-usual rate. 

Speculating on the security's next move with options could be a prudent play. The stock's Schaeffer's Volatility Index (SVI) of 23% stands higher than 23% of all other readings in its annual range, implying that options players are pricing in low volatility expectations at the moment. 

 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

SCHAEFFER'S JULY STOCKS REPORT AD
 


 


 
Special Offers from Schaeffer's Trading Partners